Memphasys WKN: A2ANGR ISIN: AU000000MEM5 Kürzel: IG7 Forum: Aktien User: Mef36

Angesichts der negativen aktuellen Auswirkungen von Covid-19, einschließlich der Abschaltung vieler unserer KOL-Kliniken und der KOLS in frühen Märkten, in denen neue optimierte Protokolle für ihre Praktiken getestet werden sollen Produktionsgeräte) rechnet das Unternehmen nun mit ersten kommerziellen KOL-Verkäufen in „frühen Märkten“ im März / April 2021.

Werde aufjedenfall bis April einfach liegen lassen eventuell sogar nachkaufen.

Hast du ne Ahnung wie viele Cash Reserven noch vorhanden sind ich hab angst das denen das geld aus geht

So langsam werd ich nervös bin bald wieder beim kauf Wert angekommen

Ich bin ausgestiegen bei 0,071, keine News, keine Zahlen, kein Volumen nicht los mit der Aktie

Highlights • Preliminary sales discussions underway with some Key Opinion Leaders(KOLs) in ‘early markets’ with low regulatory requirements. • Initial Felix KOL testing results have been positive, with recent testing with Monash IVF and University of Newcastle identifying further technique improvements which KOL partners will now incorporate into Felix assessments. • Key Opinion Leaders (KOLs) in early markets now wanting to test final Felix production cartridges which are now available, to ensure consistency with earlier results, before resuming sales discussions. • MEM continues with production of final production cartridges, positioning the Company to fill Felix commercial sales orders in early low regulatory markets from early 2021. • Initial production capability is 26,000 Felix cartridges per annum, with capacity to increase as required. • Initial sales of Felix production devices are being negotiated with prestigious Chinese medical research institutions seeking to collaborate with Professor John Aitken and his research group at University of Newcastle to expand Felix clinical utility. Australian-based bio-separations company Memphasys Limited (ASX: MEM) (“Memphasys” or “the Company”) is pleased to provide an update on the commercialisation activities for its Felix device, a novel automated device for quickly and gently separating high quality sperm from a semen sample for use in human IVF procedures. Cleanroom & Verification and Validation Memphasys has completed its initial run of the production cartridges in its cleanroom facility, located at the Sydney headquarters of manufacturer W&S Plastics. W&S has the capacity to produce approximately 100 cartridges per day (26,000 cartridges annually) within the cleanroom, with the ability to scale up substantially, depending on demand. Validation and verification testing for early markets, with cartridges from the initial production, will be completed in early January (after which time customers from early markets can receive product). Commercial KOL Sales Update Memphasys remains in regular contact with its KOL partners and in particular the KOLs in early access markets, which provide an opportunity to accelerate commercialisation of the Felix device. The Felix device has been operating as expected and initial assessment results from KOL partners has been positive, however, recent testing with Monash IVF and University of Newcastle has identified further

Meldung kam ja pünktlich zu Weihnachten.

Wenn ich aussteige explodiert der Kurs war letztes Jahr bei jeder Aktie so

Erst einmal Abwarten ob noch was kommt

Ich bin vor ein paar Tagen ausgestiegen

So langsam werd ich nervös da kommt ja gar nichts keine Meldungen oder Infos hoffentlich geht denen nicht das Geld aus

Danke Mef für die Info😀👍

Danke Mef36, mal schauen wie morgen der kurs ist . ich werde vermutlich nochmal nachlegen ein wenig . Sehe hier immer noch Verdopplungs Potential vom aktuellen Kurs.

Vom November

Highlights • Production o W&S are now manufacturing the final Production cartridges in the cleanroom, which has passed validation testing o Initial batches of the Production cartridgesshall be used to complete Verification and Validation (V&V) testing of the Felix device and for Felix KOL assessments o SRX have completed manufacture of the first Production batch of Felix consoles • Verification o Final build-quality cartridges have arrived at Hydrix for final verification tests, expected to be completed in December • Validation o Felix device validation activities will commence upon receiving sterilised Production cartridges o Felix clinical testing with these devices will take 3-4 weeks • Packaging & Sterilisation o Packaging sterility and stability tests are on track to commence upon receiving sterilised Production cartridges o Preliminary results for these will be available after 3-4 weeks • First sales of Felix device targeted for Q4 CY2020 in early markets